The molecular and cellular pathophysiology of heart failure

Heart and Lung: Journal of Acute and Critical Care

Volumn 27, Issue 1, 1998, Pages 3-19

  Piano, Mariann R ^a,b   Bondmass, Mary ^a,b   Schwertz, Dorie W ^a,c  

^a Chicago College of Nursing ^*

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CYTOKINE; ENDOTHELIN 1; MYOSIN HEAVY CHAIN; NEUROHORMONE; NORADRENALIN; PEPTIDE;

ADRENERGIC SYSTEM; CALCIUM HOMEOSTASIS; CYTOSKELETON; EXCITATION CONTRACTION COUPLING; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; INCIDENCE; MALE; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOPLASMIC RETICULUM; STARLING LAW;

EID: 0031939846     PISSN: 01479563     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0147-9563(98)90063-2     Document Type: Article

References (117)

1. Konstam M, Dracup K, Baker D, et al. Heart failure: management of patients with left-ventricular systolic function; Clinical Practice Guideline No. 11. Rockville (MD): Agency for Health Care Policy and Research, Public Health Service, US Dept HHS; 1994. AHCPR Publication No. 94-0612; 1-115.
2. Katz AM. Cardiomyopathy of overload. N Engl J Med 1991;322:100-10.
3. Williams JF. Evolving concepts in congestive heart failure, part I. Modern Concepts Cardiovasc Dis 1990;59:43-7.
4. Grossman W. Diastolic dysfunction and congestive heart failure. N Engl J Med 1991;325:1557-64.
5. Dougherty AH, Nacarelli GV, Gray EL. Congestive heart failure with normal systolic function. Am J Cardiol 1984;54: 778-82.
6. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-96.
7. Goldsmith SR, Dick C. Differentiating systolic from diastolic heart failure: pathophysiologic and therapeutic consideration. Am J Med 1993;95:645-55.
8. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994;271:1276-80.
9. National Center for Health Statistics. Vital Statistics of the United States, 1975, vol II, mortality, part A. Washington (DC): Public Health Services; 1979.
10. National Center for Health Statistics. Vital Statistics of the United States, 1984, vol II, mortality, part A. Washington (DC): Public Health Services; 1987.
11. National Center for Health Statistics. Vital Statistics of the United States, 1990, vol II, mortality, part A. Washington (DC): Public Health Services; 1994.
12. Thom T. Morbidity and mortality chartbook on cardiovascular, lung and blood diseases, 1990. Bethesda (MD): National Heart, Lung and Blood Institute; 1992.
13. Sullivan MJ. Congestive heart failure: trends in epidemiology and therapy. In: Kennedy GT, Crawford MH, editors. Congestive heart failure: current clinical issues. Armonk (NY): Futura Publishing Company, Inc; 1994.p.1-115.
14. Graves EJ. Detailed diagnosis and procedures, national hospital discharge survey, 1990. Washington DC: US Dept HHS; 1991. National Center for Health Statistics, Vital and Health Statistics series 13, No. 113, DHHS Pub No. (PHS) 92-1774.
15. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994;72(suppl):S3-59.
16. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88: 107-15.
17. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
18. Opie LH. The heart physiology and metabolism. New York: Raven Press; 1991.
19. Katz AM. Physiology of the heart. 2nd edition. New York: Raven Press; 1992.
20. Davis D, Baily R, Zelis R. Abnormalities in systemic norepinephrine kinetics in human congestive heart failure. Am J Physiol 1988;254:E760-E766.
21. Hasking GJ, Esler MD, Jennings GL, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-20.
22. Cohn JN. Plasma norepinephrine and mortality. Clin Cardiol 1995;18:19-112.
23. Francis GS, Chu C. Compensatory and maladaptive responses to cardiac dysfunction. Curr Opin Cardiol 1995;10:260-7.
24. Holtz J. Pathophysiology of heart failure and the renin-angiotensin system. Basic Res Cardiol 1993;1:183-201.
25. Paul M, Stock P, Langheinrich M, et al. Role of cardiac renin-angiotensin system in human heart failure. In: Mukhopadhyay AK, Raizada MK, editors. Tissue renin-angiotensin systems. New York: Plenum Press; 1995. p.279-83.
26. Swales JD. The renin-angiotensin system as a target for therapeutic intervention. J Cardiovasc Pharmacol 1994; 24(suppl):S1-S5.
27. Bruna RD, Kurtz A, Schricker K. Regulation of renin synthesis in the juxtaglomerular cells. Curr Opin Nephrol Hypertens 1996;5:16-9.
28. Dzau VJ, Hollenburg NK, Williams GH. The renin-angiotensin system. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, editors. The heart and cardiovascular system, vol II. New York: Raven Press; 1991.p. 1817-49.
29. Skigdel RA. Basic science aspects of angiotensin I converting enzyme and its inhibitors. In: Gathmey JW, Briggs GM, Allen PD, editors. Heart failure: basic science and clinical aspects. New York: Marcel Dekker Inc; 1993.p.399-455.
30. Dzau V J, Gibbons GH, Pratt RE. Local vascular renin-angiotensin system. Hypertension 1991;16(suppl II):100II-105II.
31. Erdos EG, Slaone EM. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol 1962;11:39-43.
32. Rose DD. Clinical physiology of acid-base and electrolyte disorders. New York: McGraw Hill; 1989.
33. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural and endocrine dependence. Circulation 1993;83:13-25.
34. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996;2:243-9.
35. Davies DR, Wlodawer A. Cytokines and their receptor complexes. FASEB J 1995;9:50-6.
36. Fong Y, Lowry SF. Cytokines and cellular response to injury and infection. In: Wilmore DW, editor. Care of the surgical patient in critical care. New York: Scientific American Publishers; 1989.p.1-22.
37. Libby P, Ross R. Cytokines and growth regulatory molecules in atherosclerosis. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven Publishers; 1996.p.585-94.
38. Levine B, Kaiman J, Mayer L, Fillit, Packer M. Elevated circulatory levels of tumor necrosis factor in severe heart failure. N Engl J Med 1990;323:336-41.
39. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulus L, Bijou R, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in forearm circulation. Circulation 1994;90:12-6.
40. Mann DL. The effect of tumor necrosis factor-alpha on cardiac structure and function: a tale of two cytokines. J Card Fail 1996;2:S165-S172.
41. Matsumori A, Yamada T, Suzuki, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathies. Br Heart J 1994;72:561-6.
42. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young- JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report for the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
43. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.
44. Cavusoglu E, Frishman WH, Klapholz M. Vesnarinone: a new inotropic agent for treating heart failure. J Card Fail 1995;3:249-62.
45. Busch FW, Tillman A, Becker EW, Owsianowski M, Berg PA. The inhibitory effects of a positive inotropic quinolone derivative, 3,4-dihydro-6-(4-[3,4-dimethoxybenzoyl]-2(1H))-quinolinone (OPC-8212), on bone marrow progenitor cells and peripheral lymphocytes. Eur J Clin Pharmacol 1992;42:629-34.
46. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. J Clin Invest 1994;94:1212-7.
47. Rodeheffer RJ, Lerman A, Heublein DM, Burneli JC Jr. Increased plasma concentration of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992;67:719-24.
48. Margulies KF, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin in experimental heart failure. Circulation 1990;82:2226-30.
49. Wei CM, Lerman A, Rodeheffer RJ, McGregor CGA, Brandt RR, Wright S, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580-6.
50. Miller W, Redfield M, Burnett JC Jr. Integrated cardiac, renal and endocrine actions of endothelin. J Clin Invest 1989;83:3117-20.
51. Ito H, Hirata Y, Hiroe M, Tsujino M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific gene in cultured neonatal rat cardiocytes. Circ Res 1991;69:209-15.
52. Moraves CS, Reynolds EE, Stewart RW, Bond E. Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun 1989;159:14-8.
53. Lerman A, Edwards BS, Hallet JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
54. Egashira K, Inou T, Hirooka Y, et al. Impaired coronary artery blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerosis. J Clin Invest 1993;91:29-37.
55. Ferrari R, Agnoletti G. Atrial natriuretic peptide: its mechanism of release from the atrium. Int J Cardiol 1989;24:137-49.
56. Ruskoaho H. Atrial natriuretic peptide: synthesis, release and metabolism. Pharmacol Rev 1992;44:479-601.
57. Edwards BS, Zimmermann RS, Burnett JC. Atrial natriuretic factor: physiological actions and implications in congestive heart failure. Cardiovasc Drugs Ther 1987;1:89-100.
58. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide (BNP) as a novel cardiac hormone in humans-evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
59. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
60. Madsen HK, Keller N, Christiansen E, Christensen NJ. Prognostic value of plasma catecholamines, plasma renin activity and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: comparison with clinical evaluation, ejection fraction, and exercise capacity. J Card Fail 1995:1:207-16.
61. Francis GS, Benedict C, Johnstone DE, et al. For the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990;82:1724-9.
62. Eriksson SV, Caidahl K, Hall C, Eneroth P, et al. Atrial natriuretic peptide ANP (1-98) and ANP (99-126) in patients with severe chronic congestive heart failure: relation to echocardiographic measurements. J Heart Fail 1995;1:109-16.
63. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic peptide in normal subjects and heart failure patients. J Clin Invest 1986;78:1362-74.
64. Clerico A, Iervasi G. Alterations in metabolic clearance of atrial natriuretic peptides in heart failure: how do they relate to the resistance to atrial natriuretic peptides? J Card Fail 1995;4:323-8.
65. Winaver J, Hoffman A, Abassi Z, Haramati A. Does the heart's hormone ANP, help in congestive heart failure? News Physiol Sci 1995;10:247-53.
66. Zak R, Kizo A, Bugaisky L. Cardiac hypertrophy: its characteristics as a growth process. Am J Cardiol 1979;44:941-56.
67. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human ventricle. J Clin Invest 1975;56:56-64.
68. Houghton IL, Carr AA, Prisant LM, et al. Morphologic, hemodynamic and coronary perfusion characteristics of severe left ventricular hypertrophy secondary to systemic hypertension and evidence for nonatherosclerotic myocardial ischemia. Am J Cardiol 1992;69:219-24.
69. Zehender M, Mainertz T, Hohnlose S, et al. Prevalence of circadian variations and spontaneous variability of cardiac disorders and ECG changes suggestive of myocardial ischemic in systemic arterial hypertension. Circulation 1992;85:808-15.
70. Tomanek RJ, Searls JC, Lachenbruch PA. Quantitative changes in the capillary bed during developing, peak and stabilized cardiac hypertrophy in the spontaneously hypertensive rat. Circ Res 1982;51:295-314.
71. Lompre AM, Schwartz K, d'Albis A, Lacombe G. Theim NV, Swyaghedauw B. Myosin isoenzyme redistribution in chronic heart overload. Nature 1979;282:105-7.
72. Schwartz K, de la Bastie D, Bouveret, Oliviero P, Alonso S, Buckingham M. Alphaskeletal muscle actin mRNA's accumulate in hypertrophied adult rat hearts. Circ Res 1986;59:551-5.
73. Leger J, Deschesne P, Bouvagnet P, Leger J-J. Contractile proteins in the normal and hypertrophied heart. In: Swynghedauw B, editor. Research in cardiac hypertrophy and failure. Montrouge (France): John Libbey Eurotext; 1990.
74. Buguaisky LB, Anderson PG, Hall RS, Bishop SP. Differences in myosin isoform expression in the subepicardial and subendocardial myocardium during cardiac hypertrophy in rat. Circ Res 1990;66:1127-32.
75. Mercadier JJ, Bouveret P, Gorza L, et al. Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circ Res 1983;53:52-62.
76. Mercadier JJ, de la Bastie D, Menasche P, et al. Alpha-myosin heavy chain isoform and atrial size in patients with various types of mitral valve dysfunction: a quantitative study. J Am Coll Cardiol 1987;9:1024-30.
77. Schwartz K, Lacarpentier Y, Martin JL, Lompre AM, Mercadier JJ, Swyaghedauw B. Myosin isoenzymic distribution correlates with speed of myocardial contraction. J Mol Cell Cardiol 1981;13:1071-5.
78. Pagani ED, Alousi AA, Grant AM, et al. Changes in myofibrillar content and Mg-ATPase activity in ventricular tissue from patients with heart failure caused by coronary artery disease, cardiomyopathy or mitral valve insufficiency. Circ Res 1988;63:380-5.
79. Arai M, Alpert NR, Maclennan DH, Barton P, Periasamy M. Alteration in sarcoplasmic gene expression in human heart failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 1993;72:463-9.
80. Brillantes A-M, Allen P, Takahashi T, Izumo S, Marks AR. Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy. Circ Res 1992;71:18-26.
81. Williams RE, Kass DA, Kawagoe Y, Pak P, Tunin RS, Shah R, et al. Endomyocardial gene expression during development of pacing tachycardia-induced heart failure in the dog. Circ Res 1994;75:615-623.
82. Arai M, Matsui H, Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 1994;74:555-64.
83. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 1994;75:434-42.
84. 2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990;85:305-9.
85. Limas CJ, Olivari MT, Goldenberg IF, et al. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 1987;21:601-5.
86. 2+ ATPase and function of the sarcoplasmic reticulum during cardiac hypertrophy. Am J Physiol 1991;261(supp 1):23-6.
87. 2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res 1989;65:1141-4.
88. 2+- transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation 1994;90:653-7.
89. 2+ release channel function in sarcoplasmic reticulum of pressure-overload-induced hypertrophic rat heart. J Mol Cell Cardiol 1994;26:1505-12.
90. Naudin V, Oliviero P, Rannou F, Sainte Beuve C, Charlemagne D. The density of ryanodine receptors decreases with pressure overload-induced rat hypertrophy. FEBS Lett 1991;285:135-8.
91. Go LO, Moschella MC, Watras J, Handa KK, Fyfe BS, Marks AR. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest 1995;95:888-94.
92. Hanf R, Drubaix I, Marotte F, Lelievre LG. Rat cardiac hypertrophy: altered sodium-calcium exchange activity in sarcolemmal vesicles. FEBS Lett 1988;236:145-9.
93. Wagner JA, Weisman HF, Snowman AM, Reynolds IJ, Weisfeldt ML, Snyder SH. Alterations in calcium antagonist receptors and sodium-calcium exchange in cardiomyopathic hamster tissue. Circ Res 1989;65:10-8.
94. Alpert NR, Hasenfuss LA, Mulieri EM, et al. The reorganization of the human and rabbit heart in response to haemodynamic overload. Eur Heart J 1992;13(suppl D):9-16.
95. Bershadsky AD, Vaziliev JM. Cytoskeleton. New York: Plenum Press; 1988.
96. Stenert PM, Jones JCR, Goldman RD. Intermediate filaments. J Cell Biol 1984;99:22s-28s.
97. Schaper J, Froede R, Hein ST, et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 1991;83:504-14.
98. Buck CA, Horwitz AF Cell surface receptors for extracellular matrix molecules. Annu Rev Cell Biol 1987;3:179-205.
99. Timpl R. Molecular aspects of the basement membrane structure. Prog Clin Biol Res 1985;171:63-74.
100. Mortin GR, Timpl R. Laminin and other basement membrane components. Annu Rev Cell Biol 1987;3:57-85.
101. Schaper J, Speiser B. The extracellular matrix in failing human heart. Basic Res Cardiol 1992:87(suppl):303-9.
102. McCormick RJ, Musch TI, Bergman BC, Thomas DP. Regional differences in LV collagen accumulation and mature cross-linking after myocardial infarction in rats. Am J Physiol 1994; 266:H354-H359.
103. Klappacher G, Franzen P, Haab D, et al. Measuring extra cellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and its impact on diagnosis and prognosis. Am J Cardiol 1995;75:913-8.
104. Zellner IL, Spinale FG, Eble DM, Hewett KW, Crawford FA. Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. Circ Res 1991;69:590-600.
105. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Circ Res 1991;83:1849-65.
106. Allen DG, Lemtosj JG. The cellular basis of the length-tension relation in cardiac muscle. J Mol Cell Cardiol 1985; 17:821-40.
107. Allen DG, Kurihara S. The effects of muscle length on intracellular calcium transients in mammalian cardiac muscle. J Physiol (London) 1982;327:79-84.
108. Lakatta EG. Starling's law of the heart explained by an intimate interaction of muscle length and myofilament calcium activation. J Am Coll Cardiol 1987;10:1157-64.
109. Noble MI. Myocardial mechanical function in rat heart failure: how should we measure it? In: Perret C, Vincent IL, editors. Update in intensive care and emergency medicine. New York: Springer-Verlag; 1988.
110. Abrams IH, Cerra F, Holcroft JL. Cardiopulmonary monitoring: care in the ICU. In: Wilmore DW, Brennan MF, Harkin AH, Hodroft JW, Meakins ML, editors. Care of the surgical patient-critical care medicine. New York: Scientific American Publications; 1989.
111. Schwinger RHG, Bohm M, Koch A, Schmidt U, Morano I, Eissner HJ, et al. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res 1994;74:959-69.
112. Komanura K, Shannon RP, Ihara T, Shen YT, Mirsky I, Bishop S, et al. Exhaustion of Frank-Starling mechanism in con scious dogs with heart faiure. Am J Physiol 1993; 265: H1119-H1131.
113. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
114. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82: 1730-6.
115. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-Heft VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity and congestive heart fail ure. Circulation 1993;87(suppl VI):V140-8.
116. Katz SD, Rao R, Berman IW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Circulation 1994;90:12-6.
117. Levine B, Kaiman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe heart failure. N Engl J Med 1990;323:236-41.